CDTX
USDCidara Therapeutics Inc. Common Stock
Echtzeitkurs
Kursdiagramm
Schlüsselkennzahlen
Marktkennzahlen
Eröffnung
$101.450
Hoch
$105.280
Tief
$100.160
Volumen
0.70M
Unternehmensfundamentaldaten
Marktkapitalisierung
2.5B
Branche
Biotechnologie
Land
United States
Handelsstatistiken
Durchschnittliches Volumen
0.84M
Börse
NCM
Währung
USD
52-Wochen-Spanne
Ähnliche Nachrichten
Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today
Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $150 Price Target
HC Wainwright & Co. analyst Sara Nik reiterates Cidara Therapeutics with a Buy and maintains $150 price target.
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive'
JP Morgan initiated coverage on Cidara Therapeutics with Overweight rating & tgt of $200, citing lead flu asset CD388's game-changing potential.
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
JP Morgan Initiates Coverage On Cidara Therapeutics with Overweight Rating, Announces Price Target of $200
JP Morgan analyst Anupam Rama initiates coverage on Cidara Therapeutics with a Overweight rating and announces Price Target of $200.
Ähnliche Aktien
Bleiben Sie auf dem Laufenden
Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.